pyrantel-pamoate and Dirofilariasis

pyrantel-pamoate has been researched along with Dirofilariasis* in 4 studies

Trials

1 trial(s) available for pyrantel-pamoate and Dirofilariasis

ArticleYear
Efficacy of ivermectin and pyrantel pamoate combined in a chewable formulation against heartworm, hookworm, and ascarid infections in dogs.
    American journal of veterinary research, 1992, Volume: 53, Issue:4

    Eight trials were conducted in dogs to document the efficacy of ivermectin (6 micrograms/kg of body weight) and pyrantel pamoate (5 mg of active pyrantel/kg) in a beef-based chewable formulation against Dirofilaria immitis, Ancylostoma caninum, Uncinaria stenocephala, Toxocara canis, and Toxascaris leonina. Three studies involved induced infection with D immitis, and 5 studies involved induced or natural infection with hookworms and ascarids. In 3 intestinal parasite trials, the efficacy of the combination chewable tablet was compared with each of its components. Results indicated that 1 component did not interfere with the activity of the other. In 1 heartworm and 2 intestinal parasite trials, the efficacy of pyrantel, ivermectin/pyrantel combination, or ivermectin with pyrantel dosage of 10 mg/kg was evaluated. The ivermectin/pyrantel combination was 100% effective in preventing development of D immitis larvae. Efficacy of the combined product against T canis, Toxascaris leonina, A caninum, and U stenocephala was 90.1, 99.2, 98.5, and 98.7%, respectively. In the intestinal parasite trials, each individual component was found not to interfere with the anthelmintic action of the other. Increasing the dosage of pyrantel to 10 mg/kg (2 x that in the combination) did not interfere with the efficacy of ivermectin against heartworm or increase the activity of pyrantel against intestinal parasites.

    Topics: Administration, Oral; Ancylostomatoidea; Ancylostomiasis; Animals; Dirofilariasis; Dog Diseases; Dogs; Drug Combinations; Female; Hookworm Infections; Intestinal Diseases, Parasitic; Ivermectin; Male; Nematode Infections; Pyrantel Pamoate; Tablets; Toxocariasis

1992

Other Studies

3 other study(ies) available for pyrantel-pamoate and Dirofilariasis

ArticleYear
Efficacy of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate for the prevention of heartworm disease in dogs.
    Research in veterinary science, 2023, Volume: 162

    Dirofilaria immitis, the mosquito-borne agent of dirofilariosis, a chronic and sometimes fatal cardiopulmonary canine disease, is endemic in most warm and temperate regions in the world. The efficacy of an oral endectoparasiticide product (test product or TP) combining moxidectin, afoxolaner, and pyrantel pamoate was evaluated for the prevention of heartworm disease in dogs, in two laboratory and one field studies. In each laboratory study, 20 D. immitis-naïve beagle dogs were experimentally infected with D. immitis. Ten control dogs were sham-treated, and ten dogs were administered the TP targeting the minimum effective dose, six times monthly and starting 30 days post infection. At necropsy seven months after inoculations, no heartworms were found in any of the TP treated dog, whereas 19 to 42 live heartworms were found in the control dogs. In each study, treatment efficacy was 100% and the difference between treated and untreated groups was highly significant (p < 0.0001). A field study was conducted through the full transmission season in several heartworm-endemic regions of the United States. One hundred and twenty client-owned dogs that were negative for D. immitis at enrollment were administered twelve monthly oral doses of the TP at label dose. Blood tests for D. immitis antigen and modified Knott's tests for microfilariae remained negative through the full duration of the study, demonstrating that all dogs were protected from heartworm infection during the full transmission season. These studies demonstrated that TP administered monthly for at least six doses is effective at preventing dirofilariosis.

    Topics: Animals; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Heart Diseases; Macrolides; Pyrantel Pamoate; United States

2023
Pharmacokinetics of [3H]-ivermectin in the dog following oral administration of a beef-based chewable formulation containing ivermectin alone or in combination with pyrantel pamoate.
    Journal of veterinary pharmacology and therapeutics, 1992, Volume: 15, Issue:2

    Topics: Absorption; Administration, Oral; Analysis of Variance; Animals; Biological Availability; Dirofilariasis; Dog Diseases; Dogs; Drug Combinations; Female; Ivermectin; Pyrantel Pamoate; Random Allocation; Therapeutic Equivalency

1992
Safety study of a beef-based chewable tablet formulation of ivermectin and pyrantel pamoate in growing dogs, pups, and breeding adult dogs.
    American journal of veterinary research, 1992, Volume: 53, Issue:4

    To determine the safety of a new combination of ivermectin and pyrantel (as pamoate salt) in a novel beef-based chewable tablet formulation, 3 tolerance trials were conducted and included growing dogs, pups, and breeding adult dogs. Growing dogs, given the combination orally for 5 consecutive days at recommended dosages (5 mg of pyrantel/kg of body weight, 6 micrograms of ivermectin/kg) or at twice the pyrantel dosage in combination with the recommended dosage of ivermectin, had no adverse effects. The combination also was administered to 6-week-old pups at 1, 3, and 5 times the recommended dose on 3 successive days for 3 times in 1 month. Compared with age-matched controls, treatment had no effect on clinical status, growth rate, or gross or histologic features. Breeding male and female dogs given the combination at 3 times the recommended dose for extended periods had no adverse effects, and prevalence of abnormalities in the offspring was not greater than that in nonmedicated controls.

    Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Dirofilariasis; Dog Diseases; Dogs; Drug Combinations; Drug Tolerance; Female; Fertility; Fertilization; Ivermectin; Litter Size; Male; Pyrantel Pamoate; Random Allocation; Reproduction; Tablets

1992